Adaptive Biotechnologies

Recent news

• Rating change
  Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Cuts Target Price to $13.54
  Market Newswire · 2026/5/12
• Rating change
  Guggenheim Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $22
  Market Newswire · 2026/6/29
• Rating change
  Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $20
  Market Newswire · 2026/5/12
• Rating change
  Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $27.5
  Market Newswire · 2026/8/24
• Rating change
  Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Biomea Fusion (BMEA) and Adaptive Biotechnologies (ADPT)
  TipRanks · 2026/5/12
• Rating change
  William Blair Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating
  Market Newswire · 2026/6/17
• Adaptive Biotechnologies(ADPT.US) Officer Sells US$3.24 Million in Common Stock
  Market Newswire · 2026/9/19
• BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $34
  Market Newswire · 2026/9/22
• Rating change
  Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Maintains Target Price $21
  Market Newswire · 2026/2/10
• Rating change
  A Quick Look at Today's Ratings for Adaptive Biotechnologies(ADPT.US), With a Forecast Between $20 to $22
  Market Newswire · 2026/2/7
• Rating change
  Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $27.5
  Market Newswire · 2026/8/4
• Rating change
  A Quick Look at Today's Ratings for Adaptive Biotechnologies(ADPT.US), With a Forecast Between $25 to $28
  Market Newswire · 2026/7/31
• Guggenheim Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $32
  Market Newswire · 2026/10/1
• BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $34
  Market Newswire · 2026/9/22
• Goldman Sachs Initiates Adaptive Biotechnologies(ADPT.US) With Buy Rating, Announces Target Price $35
  Market Newswire · 2026/9/29
• Rating change
  BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $24
  Market Newswire · 2026/7/23
• Rating change
  A Quick Look at Today's Ratings for Adaptive Biotechnologies(ADPT.US), With a Forecast Between $19 to $22
  Market Newswire · 2026/5/6
• Rating change
  TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $25
  Market Newswire · 2026/7/15
• Rating change
  Craig-Hallum Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating
  Market Newswire · 2026/9/18
• Rating change
  Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN), RegenXBio (RGNX) and Adaptive Biotechnologies (ADPT)
  TipRanks · 2026/2/10

Headlines are aggregated automatically and are not independently verified or edited by our team.